2015年12月2日，北京：爱康集团（以下称为“公司”）董事会于今日通过一份股东权益协议，授权就每一股已发行的A类和C类普通股发放一份股份认购权（以下称为“权益计划”）。此前，公司的独立董事组成了一个特别委员会（以下称为“特别委员会”）以考虑公司进行“私有化”的可能性；公司的董事会（以下称为“董事会”）在经过慎重考虑后认为，为了保证在特别委员会领导的工作进程外出现未经邀请意欲收购公司的情况时，公司全体股东能够得到公平、平等的待遇，在当下采取权益计划是合理和审慎的选择。
公司早前在2015年9月10日已经披露，在公司创始人、董事长和首席执行官张黎刚先生（以下称为“张先生”）及其本人若干关联实体以及方源资本递交了一份非约束性的“私有化”提案（以下称为“创始人买方团提案”）后，特别委员会随之成立。随后，江苏三友集团股份有限公司、凯辉私募股权投资基金、深圳市平安德成投资有限公司、太平国发（苏州）资本管理有限公司、北京红杉坤德投资管理中心（有限合伙）以及华泰瑞联基金管理有限公司递交了一份非约束性的“私有化”提案（以下称为“江苏三友买方团提案”）与之竞争。
特别委员会将在其独立的财务顾问和法律顾问的协助下仔细考虑和评估江苏三友买方团提案、创始人买方团提案以及公司的其他战略选择。采取权益计划将保证独立委员会和董事会能够获得充足的时间来妥当地考察和进一步发掘符合公司及其股东的最佳利益的任何其他战略选择，并且不会妨碍独立委员会或董事会考察或接受任何收购提案，只要董事会（依据特别委员会作出的推荐）认定该等收购提案是公平、可取且符合公司及其股东的最佳利益的。
根据该权益计划，在以下两者较早之一之前，认购权将在普通股凭证上登记、与普通股一起自动交易并且不能被行使：(i)公司宣布某个人或集团（“收购方”）已获得公司A类普通股的10%或更多，或是任何收购方获得公司A类普通股的50%以上（两种情况的发生日期均称为“弹入触发日”），以及(ii)任何个人或集团发出将使其拥有公司A类普通股的10％或以上的现金或股权收购要约之后的第10个工作日或是董事会决定的更晚的日期。此后，认购权凭证将会发放，持有人凭一份认购权可以以80美元的价格购买一股A类普通股。
在弹入触发日到来时，认购权持有人凭每一份认购权（任何由收购方实益持有或转让的认购权除外，这部分认购权将归于无效）将可以以认购价购买市值为认购价两倍的公司A类普通股。另外，如果在一名收购方控制了公司的董事会或持有公司A类普通股50%或以上之后，公司发生合并且收购方在该合并中获得与所有其他股东不同的待遇或者收购方是该次合并交易的对家，又或者公司出售超过其资产、运营收入或现金流的50%的资产，认购权持有人凭每一份认购权可以以认购价购买由收购方持有的、市值为认购价两倍的普通股。如果任何个人或集团购得公司A类普通股的10%至50%，董事会可以决定以一股A类普通股交换一份认购权。
确定有资格获得认购权的公司股东的确权日期是2015年12月13日。权益计划将不晚于2016年12月2日终止，除非董事会选择续期。
认购权只能由特别委员会在弹入触发日前以每份0.001美元的价格赎回。权益计划可以由公司（在特别委员会的推荐或指引下）修改。
关于权益协议和权益协议特定条款概要的一封信将会被寄给股东。
就以上事宜，公司聘请苏利文·克伦威尔律师事务所为其美国法顾问，聘请康德明律师事务所为其开曼法顾问。
关于爱康集团
爱康集团（iKang Healthcare Group）是中国收入规模最大的私营预防医疗服务供应商，在2014自然年度约占13.6%的市场份额。依托旗下的健康体检和医疗服务中心、IT技术平台和强大的客户服务体系，每年为数百万客户提供健康体检、疾病检测、私人医生、齿科服务、职场医疗等健康管理服务。
截至2015年11月30日，爱康已在中国22个城市设有80家1体检与医疗中心，包括香港、北京、上海、广州、深圳、重庆、天津、南京、苏州、杭州、成都、福州、长春、江阴、常州、武汉、长沙、烟台、银川、威海、潍坊和沈阳。同时，爱康国宾集团与全国150个城市的约400家医疗机构建立合作网络，从而为客户提供全国一站式的健康体检和健康管理服务。
（1）80家体检与医疗中心中，有两家目前主要由该体检医疗中心或其母公司的小股东所运营.
媒体垂询
爱康集团
Christy Xie
投资者关系总监
电话： +86 10 5320 8599
邮件: ir@ikang.com
网站: www.ikanggroup.com
FleishmanHillard
Email: ikang.ir@fleishman.com
iKang Healthcare Group, Inc.ADOPTS RIGHTS AGREEMENT
BEIJING,December 2, 2015-- The Board of Directors of iKang Healthcare Group, Inc. (the“Company”) today adopted a Rights Agreement and authorized the issuance of oneRight for each outstanding Class A Common Share and Class C Common Share (the“Rights Plan”). After carefulconsideration, the Board of Directors of the Company (the “Board”) deemed itappropriate and prudent to adopt the Rights Plan at this time in order toensure that all shareholders of the Company receive fair and equal treatment inthe event that an unsolicited attempt is made to acquire the Company outside ofthe process led by the special committee of independent directors of theCompany (the “Special Committee”), which was formed to consider the possibilityof a “going private” transaction involving the Company.
As disclosed onSeptember 10, 2015, the Special Committee was formed following the submissionof a non-binding “going private” proposal by Ligang Zhang (“Mr. Zhang”),founder, chairman and chief executive officer of the Company and certain of hisaffiliated entities, and FV Investment Holdings (the “Founder Buyer GroupProposal”). Subsequently, a non-bindingcompeting “going private” proposal was submitted by Jiangsu Sanyou Group Co.,Ltd., Cathay Capital Private Equity SAS, Shenzhen Ping An Decheng InvestmentCo., Ltd., Taiping Guofa (Suzhou) Capital Management Co., Ltd., Sequoia ChinaInvestment Management LLP and Huatai Ruilian Fund Management Co., Ltd. (the“Jiangsu Sanyou Buyer Group Proposal”).
The SpecialCommittee will carefully consider and evaluate, with the assistance of theSpecial Committee’s independent financial and legal advisors, the JiangsuSanyou Buyer Group Proposal, the Founder Buyer Group Proposal and the Company’sstrategic alternatives. The adoption ofthe Rights Plan will ensure that the Special Committee and the Board havesufficient time to duly consider and pursue any strategic alternatives of theCompany that are in the best interests of the Company and its shareholders, anddoes not prevent the Special Committee or the Board from considering oraccepting any acquisition proposal if the Board (acting upon the recommendationof the Special Committee) determines that such action is fair, advisable and inthe best interests of the Company and its shareholders.
Pursuant to theRights Plan, until the earlier of (i) the Company’s announcement that a personor group has acquired 10% or more of the Company’s Class A Common Shares (an“Acquiring Person”) or the date and time on which any Acquiring Person hasacquired more than 50% of the Company’s Class A Common Shares (in either case,the “Flip-in Date”) and (ii) the tenth business day, or such later datedesignated by the Board, after anyperson or group commences a tender or exchange offer that will result in suchperson or group owning 10% or more of the Company’s Class A Common Shares, theRights will be evidenced by the Common Share certificates, will automaticallytrade with the Common Shares and will not be exercisable. Thereafter, separate Rights certificates willbe distributed and each Right will entitle its holder to purchase one Class ACommon Share for an exercise price of $80.
Upon the occurrence of the Flip-in Date, eachRight (other than Rights beneficially owned by any Acquiring Person ortransferees thereof, which Rights become void) will entitle its holder topurchase, for the exercise price, a number of the Company’s Class A CommonShares having a market value of twice the exercise price. Also, if after an Acquiring Person controls the Company’s Board of Directors or isthe owner of 50% or more of the Company’s Class A Common Shares, the Company is involved in a merger or sellsassets representing more than 50% of its assets, operating income or cash flowand, in the case of a merger, the Acquiring Person will receive different treatmentthan all other shareholders or the transaction is with the Acquiring Person,each Right will entitle its holder to purchase, for the exercise price, anumber of shares of common shares of the Acquiring Person having a market valueof twice the exercise price. If anyperson or group acquires between 10% and 50% of the Company’s Class A CommonShares, the Board may, at its option, exchange one share of the Company’s ClassA Common Stock for each Right.
The record dateto determine shareholders of the Company entitled to receive the Rights isDecember 13, 2015. The Rights Plan willexpire no later than December 2, 2016 unless renewed by the Board.
The Rights maybe redeemed exclusively by the Special Committee for $0.001 per Right prior tothe Flip-in Date, and the Rights Plan may be amended by the Company (actingupon the recommendation or direction of the Special Committee).
A letter toshareholders regarding the Rights Agreement and a Summary of certain terms ofthe Rights Agreement will be mailed to shareholders.
The Companyretained Sullivan & Cromwell LLP as its U.S. legal adviser and Conyers Dill& Pearman as its Cayman Islands legal adviser in connection with theforegoing.
About iKang Healthcare Group,Inc.
iKang Healthcare Group, Inc. isthe largest provider in China’s fast growing private preventive healthcareservices market, accounting for approximately 13.6% of market share in terms ofrevenue in calendar year 2014.
Through iKang’s integratedservice platform and established nationwide network of medical centers andthird-party service provider facilities, the Company provides comprehensive andhigh quality preventive healthcare solutions, including a wide range of medicalexaminations services and value-added services including disease screening andother services. iKang’s customers are primarily corporate customers whocontract the Company to provide medical examination services to their employeesand clients, and pay for these services at pre-negotiated prices. iKang alsodirectly markets its services to individual customers. In the fiscal year endedMarch 31, 2015, the Company served a total of 3.6 million customer visits underboth corporate and individual programs. For the first six months endedSeptember 30, 2015, the Company served a total of 2,281,000 customer visits.
As of November 30, 2015, iKang’snationwide network consisted of 80 (1) self-owned medicalcenters covering 22 of the most affluent cities in China, namelyBeijing, Shanghai, Guangzhou, Shenzhen, Chongqing, Tianjin, Nanjing, Suzhou,Hangzhou, Chengdu, Fuzhou, Changchun, Jiangyin, Changzhou, Wuhan, Changsha,Yantai, Yinchuan, Weihai, Weifang and Shenyang, as well as Hong Kong. TheCompany has also supplemented its self-owned medical center network bycontracting with approximately 400 third-party service provider facilities inover 150 cities, which include selected independent medical examination centersand hospitals across all of China’s provinces, creating a nationwide networkthat allows iKang to serve its customers in markets where it does not haveself-owned medical centers.
(1) Among the 80 self-ownedmedical centers, two medical centers are currently operated primarily by theminority shareholders of these medical centers or their parent company.
For additionalinformation, contact:
iKangHealthcare Group, Inc.
ChristyXie
Directorof Investor Relations
Tel:+86 10 5320 8599
Email: ir@ikang.com
Website:www.ikanggroup.com
FleishmanHillard
Email:ikang.ir@fleishman.com
iKang Healthcare Group Inc